Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared a post on X:
“Biomarkers are coming in renal cancer.
KIM1 is most promising but we don’t have definitions of positivity and have different assays getting different results. It’s also not been part of a prospective trial.
Many biomarkers fail at these hurdles. ctDNA seems to lack sensitivity. Maybe we can combine the 2?”
More posts featuring Thomas Powles on OncoDaily.